ClinicalTrials.gg
CompletedNCT06212804Updated Apr 24, 2026Results posted

A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

A Phase 1 interventional study of VIS954 and Placebo in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.

Read the detailed description

The study will be conducted in 6 sequential cohorts. Each cohort will enroll 9 participants, randomized to VIS954 or placebo at a ratio of 7:2.

On Day 1, a single dose of VIS954 or placebo will be administered SC. Sentinel participants will be utilized in each cohort. After 14 days, the safety data will be evaluated and a decision to admit and dose the next cohort will be made.

The total duration of the clinical study per participant will be up to 102 days (approximately 4 months).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participant between 18 to 55 years of age, inclusive, at the screening visit.
  2. Non-Japanese participant: Participant does not meet the criteria specified below for 'Japanese Participant'.
  3. Japanese participant: Participant is of Japanese descent as evidenced by verbal confirmation of familial heritage (a participant's 4 grandparents were born in Japan and recognized to be 'Japanese').
  4. between 18.0 and 30.0 kg/m2, inclusive, at the screening visit.
  5. Total body weight between 50.0 and 120.0 kg, inclusive, at the screening visit.
  6. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.
  7. Willing and able to participate in the study for the defined duration of the study.
  8. Female participants will be nonpregnant, nonlactating, and either for at least 1 year or surgically sterile for at least 3 months, or will agree to use highly effective methods of from the period prior to study enrollment until 30 days after Day 56; women of must have a negative serum beta-human chorionic gonadotropin (β-hCG) test at screening and a negative urine pregnancy test at baseline prior to administration of the study intervention.
  9. Male participants with female partners of childbearing potential must agree to use double barrier contraception or abstain from sex during the study and until 90 days after Day 56. Male participants must agree to refrain from sperm donation for the duration of the study and until 90 days after Day 56. This criterion may be waived for male participants who have had a vasectomy greater than 6 months prior to enrollment.
  10. Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluations), as judged by the principal investigator.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, , blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or . History of minor skin cancers (not including melanoma) or surgically treated, limited cervical carcinomas (ie, carcinoma in situ) are not exclusionary.
  2. Participant is participating in another clinical study of any drug, device, or intervention or has received any investigational medication during the last 30 days or 5 half-lives, whichever is longer, before baseline (Day -1).
  3. Previous receipt of antibody or biologic therapy.
  4. History of a previous or severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any of the ingredients of the VIS954 SC injection formulation.
  5. Blood pressure > 160/100 mmHg or \< 90/50 mmHg (may be repeated once if abnormal), at the screening visit or Day -1.
  6. History of any infection requiring hospitalization or treatment with antivirals, antibiotics, or systemic antifungals within 3 months prior to screening.
  7. Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose.
  8. Has received any prescription or nonprescription (over-the-counter) medication during the last 30 days or 5 half-lives, whichever is longer, preceding baseline (Day -1), with the exception of acetaminophen, ibuprofen, naproxen (or other over-the-counter nonsteroidal anti-inflammatory drugs [NSAID]), hormonal , topical medications, vitamins, and dietary or herbal remedies.
  9. Any participant who has a recent history of alcohol or drug/chemical abuse, at the discretion of the investigator, will be excluded.
  10. Enrolled participants must abstain from consumption of nicotine containing products from Day -1 through discharge.
  11. Enrolled participants must abstain from consumption of cannabinoids from Day-1 through end of study.
  12. For the duration of the study, enrolled male participants should not consume more than 15 standard drinks per week (7 days) and female participants should not consume more than 10 standard drinks per week (7 days). A standard drink equals 10 g of alcohol. Enrolled participants must abstain from consuming alcohol 48 hours prior to check-in on Day -1 through discharge.
  13. Participant with a positive urine drug or alcohol breath screen test result at screening or Day -1. The urine drug screen and alcohol breath screen may be repeated once at the discretion of the investigator. The urine drug screen also screens for methylenedioxymethamphetamine and propoxyphene. If a participant tests positive on these tests, inclusion of that participant into the study will be based on the principal investigator's judgment with consultation, as needed, with the medical monitor and the sponsor.
  14. Any chronic infectious disease (eg, chronic urinary tract infection, chronic sinusitis, bronchiectasis, active pulmonary or systemic tuberculosis [TB], chronic viral hepatitis such as or , or [HIV] infection).
  15. Participant who has donated > 500 mL of blood within 60 days prior to start of the screening visit or the participant has donated any plasma within 7 days prior to baseline (Day -1).
  16. Coronavirus disease 2019:

    • Current symptoms of infection.
    • Diagnosis of COVID-19 (reverse transcription polymerase chain reaction [RT-PCR], antigen testing, or clinical diagnosis) in the 21 days prior to screening.
    • Ongoing diagnosis of "Long-COVID" symptoms, due to a prior COVID-19 infection.
  17. Is an employee of the clinical research team (any sponsor or research site employee), or has a family member who is an employee of these organizations.
  18. Participant is judged by the investigator or the medical monitor to be inappropriate for the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    VIS954 Dose 1

    A single VIS954 Dose 1 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Experimental
    VIS954 Dose 2

    A single VIS954 Dose 2 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Experimental
    VIS954 Dose 3

    A single VIS954 Dose 3 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Experimental
    VIS954 Dose 4

    A single VIS954 Dose 4 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Experimental
    VIS954 Dose 5

    A single VIS954 Dose 5 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Experimental
    VIS954 Dose 6

    A single VIS954 Dose 6 will be administered subcutaneously on Day 1

    Biological: VIS954

  • Placebo comparator
    Placebo

    A single Placebo dose will be administered subcutaneously on Day 1 for 2 participants in each cohort.

    Other: Placebo

Interventions

  • BiologicalVIS954

    A humanized IgG4 monoclonal antibody.

  • OtherPlacebo

    VIS954 Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.

    Time frame: From study intervention administration (Day 1) up to end of follow-up (Day 71)

  2. Wong-Baker FACES Pain Rating Scale

    The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented "no hurt" to a crying face at 10 which represented "hurts worst." Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.

    Time frame: Day 1 (1 and 4 hours post-dose), Day 2 (24 hours post-dose), and on Days 3 and 29

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The pharmacokinetic (PK) parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  2. Time of Maximum Serum Concentration (Tmax) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  3. Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  4. Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  5. Apparent Terminal Elimination Half-Life (t1/2) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  6. Apparent Volume of Distribution (Vd/F) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  7. Apparent Clearance After Extravascular Dosing (CL/F) of VIS954

    Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

    Time frame: Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71

  8. Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils

    Blood samples were collected at the specified time points to characterize the effect of VIS954 binding. The time spent above 40% RO was defined as duration in hours from date and time of dosing until the date and time of pharmacodynamic (PD) collection when %RO \>40%. Baseline was defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments).

    Time frame: Baseline (Day -1) up to Day 71

07

Results

Posted Jul 14, 2025

Participant flow

This Phase 1, double-blind, single ascending dose, first-in-human study was conducted in healthy participants at a single investigational site.

Participant flow — Overall Study
MilestoneCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled Placebo
Started77777712
Completed77777712
Not completed0000000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.

Time frame:
From study intervention administration (Day 1) up to end of follow-up (Day 71)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled Placebo
TEAEs2111324
TESAEs0000000
PrimaryWong-Baker FACES Pain Rating Scale

The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented "no hurt" to a crying face at 10 which represented "hurts worst." Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.

Time frame:
Day 1 (1 and 4 hours post-dose), Day 2 (24 hours post-dose), and on Days 3 and 29
Reported as:
Mean · units on a scale
Wong-Baker FACES Pain Rating Scale
units on a scaleCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled Placebo
Day 1: 1 hour post-dose0 ± 00 ± 00 ± 00.3 ± 0.80 ± 00 ± 00.3 ± 1.2
Day 1: 4 hours post-dose0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00.3 ± 1.2
Day 2: 24 hours post-dose0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Day 30 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Day 290 ± 00 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
SecondaryMaximum Serum Concentration (Cmax) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The pharmacokinetic (PK) parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Serum Concentration (Cmax) of VIS954
micrograms per milliliter (mcg/mL)Cohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Maximum Serum Concentration (Cmax) of VIS954—0.0660 ± NA1.961 ± 1.3784.423 ± 2.85116.82 ± 12.9532.61 ± 12.00
SecondaryTime of Maximum Serum Concentration (Tmax) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Median · hour
Time of Maximum Serum Concentration (Tmax) of VIS954
hourCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Time of Maximum Serum Concentration (Tmax) of VIS954—48.00 (48.00 to 48.00)48.00 (4.02 to 98.35)71.82 (48.00 to 166.38)74.02 (72.12 to 169.70)95.60 (48.00 to 169.70)
SecondaryArea Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Mean · hour*mcg/mL
Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954
hour*mcg/mLCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954——395 ± NA1463 ± 13245529 ± 187711560 ± 5503
SecondaryArea Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Mean · hour*mcg/mL
Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954
hour*mcg/mLCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954—3.17 ± NA188.4 ± 151.2872.4 ± 974.13604 ± 268411470 ± 5458
SecondaryApparent Terminal Elimination Half-Life (t1/2) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Median · hour
Apparent Terminal Elimination Half-Life (t1/2) of VIS954
hourCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Apparent Terminal Elimination Half-Life (t1/2) of VIS954——85.25 (37.5 to 133)33.6 (25.8 to 105)48.0 (41.3 to 82.4)76.3 (44.7 to 101)
SecondaryApparent Volume of Distribution (Vd/F) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Mean · liter
Apparent Volume of Distribution (Vd/F) of VIS954
literCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Apparent Volume of Distribution (Vd/F) of VIS954——12.3 ± NA10.12 ± 1.7975.218 ± 1.6068.536 ± 5.579
SecondaryApparent Clearance After Extravascular Dosing (CL/F) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.

Time frame:
Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71
Reported as:
Mean · liter per hour
Apparent Clearance After Extravascular Dosing (CL/F) of VIS954
liter per hourCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6
Apparent Clearance After Extravascular Dosing (CL/F) of VIS954——0.228 ± NA0.1864 ± 0.11080.06911 ± 0.023580.07976 ± 0.05542
SecondaryTime Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils

Blood samples were collected at the specified time points to characterize the effect of VIS954 binding. The time spent above 40% RO was defined as duration in hours from date and time of dosing until the date and time of pharmacodynamic (PD) collection when %RO \>40%. Baseline was defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments).

Time frame:
Baseline (Day -1) up to Day 71
Reported as:
Median · hour
Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils
hourCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled Placebo
Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils0.0 (0.0 to 0.0)48.0 (0.0 to 74.1)239.2 (215.8 to 314.1)335.5 (239.7 to 671.4)503.1 (217.0 to 673.7)1008.1 (838.9 to 1680.0)0.0 (0.0 to 0.0)

Adverse events

Collected over From study intervention administration (Day 1) up to end of follow-up (Day 71). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: VIS954 Dose 10/7 (0%)0/7 (0%)2/7 (28.6%)
Cohort 2: VIS954 Dose 20/7 (0%)0/7 (0%)1/7 (14.3%)
Cohort 3: VIS954 Dose 30/7 (0%)0/7 (0%)1/7 (14.3%)
Cohort 4: VIS954 Dose 40/7 (0%)0/7 (0%)1/7 (14.3%)
Cohort 5: VIS954 Dose 50/7 (0%)0/7 (0%)3/7 (42.9%)
Cohort 6: VIS954 Dose 60/7 (0%)0/7 (0%)2/7 (28.6%)
Cohort 1 to 6: Pooled Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventCohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled Placebo
Injection site reactionGeneral disorders0/70/70/71/72/71/73/12
Blood loss anaemiaBlood and lymphatic system disorders0/71/70/70/70/70/70/12
DiarrhoeaGastrointestinal disorders0/70/70/71/70/70/70/12
Injection site bruisingGeneral disorders1/70/70/70/70/70/70/12
Injection site pruritusGeneral disorders0/70/70/71/70/70/71/12
ArthralgiaMusculoskeletal and connective tissue disorders0/70/70/70/71/70/70/12
HeadacheNervous system disorders1/70/71/70/70/70/71/12
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/70/70/70/70/71/70/12
NauseaGastrointestinal disorders0/70/70/70/70/70/71/12
Upper respiratory tract infectionInfections and infestations0/70/70/70/70/70/71/12

Baseline characteristics

The safety analysis set included all participants who received trial intervention (active or placebo).

Age, Continuous
Age, Continuous(years)Cohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled PlaceboTotal
Mean35.4 ± 8.240.6 ± 8.138.9 ± 9.639.0 ± 7.739.4 ± 9.339.0 ± 10.236.5 ± 7.638.2 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled PlaceboTotal
Female544423729
Male233354525
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled PlaceboTotal
Hispanic or Latino110212310
Not Hispanic or Latino667565944
Unknown or Not Reported00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: VIS954 Dose 1Cohort 2: VIS954 Dose 2Cohort 3: VIS954 Dose 3Cohort 4: VIS954 Dose 4Cohort 5: VIS954 Dose 5Cohort 6: VIS954 Dose 6Cohort 1 to 6: Pooled PlaceboTotal
Black132100411
Asian432463123
White211113514
Other00010012
Multiple00200114
08

Study locations

1 site
  • Visterra Clinical Site
    Anaheim, California 92801, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jul 2024, 7 months.

Results were first posted in Jul 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 19, 2024
StartActual
Nov 21, 2023
Primary completionActual
Jul 19, 2024
CompletionActual
Jul 19, 2024
Results first posted
Jul 14, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06212804
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Nov 21, 2023
Primary completion
Jul 19, 2024
Completion
Jul 19, 2024
Results posted
Jul 14, 2025
Last update
Apr 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VIS954

Start the discussion